MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aratana Therapeutics Company Profile (NASDAQ:PETX)

Consensus Ratings for Aratana Therapeutics (NASDAQ:PETX) (?)
Ratings Breakdown: 1 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $14.14 (133.00% upside)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)
Show:
DateFirmActionRatingPrice TargetActions
4/26/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Jefferies GroupReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Stifel NicolausLower Price TargetBuy$12.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015BarclaysReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Piper JaffrayReiterated RatingOverweight$25.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015Lake Street CapitalInitiated CoverageBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015JMP SecuritiesSet Price TargetBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Bank of AmericaBoost Price Target$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Aratana Therapeutics (NASDAQ:PETX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q215($0.36)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.40)($0.41)
Q2 20162($0.43)($0.41)($0.42)
Q3 20163($0.43)($0.39)($0.41)
Q4 20162($0.40)($0.34)($0.37)
Q1 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)
Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Aratana Therapeutics (NASDAQ:PETX)
DateHeadline
06/28/16 10:39 AMShare Update and Earnings Review for Aratana Therapeutics, Inc. (NASDAQ:PETX) - Press Telegraph
06/28/16 10:39 AMAratana Therapeutics Incorporated (NASDAQ:PETX) Shorted Shares Increased By 6.12% - Engelwood Daily
06/28/16 10:39 AMStrong Sell Calls Recommendations For Aratana Therapeutics, Inc. (NASDAQ:PETX) At 0 - Investor Newswire
06/24/16 05:51 PMCovering the Bases on Aratana Therapeutics, Inc. (NASDAQ:PETX): Where is the Stock Going? - Press Telegraph
06/24/16 05:51 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 06:22 PMStock Buzz: Aratana Therapeutics, Inc. (NASDAQ:PETX) - iStreetWire
06/23/16 06:22 PMAratana Therapeutics, Inc. (PETX) Current Analyst Ratings - Fiscal Standard
06/21/16 05:19 PMStrong Buy Calls Count For Aratana Therapeutics, Inc. (NASDAQ:PETX) At 5 - Investor Newswire
06/10/16 06:03 PMWill Aratana Therapeutics, Inc. (NASDAQ:PETX) Surprise Analysts? - Investor Newswire
06/08/16 06:12 PMARATANA THERAPEUTICS INC. (NASDAQ:PETX) Financial Condition Compared to S&P 500 - CML News
06/05/16 05:46 PMAratana Therapeutics, Inc. (PETX) Broker Price Targets For The Coming Week - Share Trading News
06/02/16 06:11 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Change In Inventory At $-0.879 Millions - RealistInvestor.com - Aratana Therapeutics, Inc. (NASDAQ:PETX) Change In Inventory At $-0.879 MillionsRealistInvestor.comAratana Therapeutics, Inc. (NASDAQ:PETX) accounts payable was $1.4 millions for the fiscal closed 2015-12-31. For the quarter ended 2015-12-31 it was $1.4 millions. At the end of the year 2015-12-31, the deviation in accounts payable was $-0.117 ...
06/02/16 06:11 PMAratana Therapeutics (PETX) Is Strong On High Volume Today - TheStreet.com - TheStreet.comAratana Therapeutics (PETX) Is Strong On High Volume TodayTheStreet.comAratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Currently there are 5 analysts that rate Aratana ...and more »
06/02/16 08:46 AMAratana Therapeutics, Inc. (PETX) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Aratana Therapeutics, Inc. (PETX) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Aratana Therapeutics, Inc. (PETX). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
06/02/16 08:23 AMAratana Therapeutics Receives CMC Technical Section Complete Letter for Post-Operative Pain Therapeutic - [PR Newswire] - LEAWOOD, Kan., June 2, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical ...
06/01/16 06:17 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Quarterly EPS Estimate At $-0.39 - Investor Newswire - Aratana Therapeutics, Inc. (NASDAQ:PETX) Quarterly EPS Estimate At $-0.39Investor NewswireFirst Call stated that Aratana Therapeutics, Inc. (NASDAQ:PETX) can touch $12.33 in coming one year. For the next quarter, the per-share earnings target is $-0.39 and for ongoing fiscal at $-1.08. EPS target for next year is $-1.05 versus the mean EPS ...and more »
06/01/16 08:42 AMAratana Therapeutics Inc. (PETX) Jumps 9.98% on May 30 - Equities.com - Aratana Therapeutics Inc. (PETX) Jumps 9.98% on May 30Equities.comAratana Therapeutics Inc. (PETX) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 9.98% to $6.83, representing a gain of $0.62 per share. Some 939,224 shares traded hands on 4,850 trades, compared with an ...and more »
05/31/16 06:02 PMThree Stocks You Must Add Into Your Portfolio: Aratana Therapeutics Inc (NASDAQ:PETX), Novavax, Inc. (NASDAQ ... - The Point Review - Three Stocks You Must Add Into Your Portfolio: Aratana Therapeutics Inc (NASDAQ:PETX), Novavax, Inc. (NASDAQ ...The Point ReviewShares of Aratana Therapeutics Inc (NASDAQ:PETX) flew 6.15% to $7.25 at 12:34 PM EDT. The stock attained the volume of 854,463 shares recently versus average trading volume of 800.189 Million shares. If we take a look on its volatility, 5.76 percent ...How Many Aratana Therapeutics Inc (NASDAQ:PETX)'s Analysts Are Bullish?Franklin IndependentMicrocap Volatile Stocks: Aratana Therapeutics, Inc. (NASDAQ:PETX), Jones Energy, Inc. (NYSE:JONE), Legacy ...Benchmark Monitorall 7 news articles »
05/31/16 09:35 AMHealthcare Stocks Review: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Aratana Therapeutics, Inc. (NASDAQ:PETX) - Is stories - Healthcare Stocks Review: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Aratana Therapeutics, Inc. (NASDAQ:PETX)Is storiesIn most recently trading session on 5/27/2016, Aratana Therapeutics, Inc. (NASDAQ:PETX) climbed +9.98% while traded on 939.22 thousand shares versus it's an average volume of 862.46 thousand shares. The company recorded the last trade with the price ...and more »
05/28/16 09:56 AMHold Calls Count For Aratana Therapeutics, Inc. (NASDAQ:PETX) At 1 - RealistInvestor.com - Hold Calls Count For Aratana Therapeutics, Inc. (NASDAQ:PETX) At 1RealistInvestor.comBuy calls count on Aratana Therapeutics, Inc. (NASDAQ:PETX)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 1. Aratana Therapeutics, Inc. (NASDAQ:PETX) has a total of 5 Strong Buy recommendations and 0 Strong Sell ...and more »
05/28/16 09:56 AMCrowd Views on: Aratana Therapeutics Inc (NASDAQ:PETX) - The Point Review - The Point ReviewCrowd Views on: Aratana Therapeutics Inc (NASDAQ:PETX)The Point ReviewShare of Aratana Therapeutics Inc (NASDAQ:PETX) traded on 8.70 percent above secure line at 3:30PM EDT in order to take the company's stock at the price of $6.74. At the time of writing the stock exchanged hands 727,787 shares versus average trading ...Aratana Therapeutics Inc. (PETX) Jumps 9.98% on May 27Equities.comWorth Watching Stock: Aratana Therapeutics, Inc. (NASDAQ:PETX)CWRU ObserverRecently Changed Price Targets On Aratana Therapeutics, Inc. (PETX)Risers & FallersMarkets Daily -The Postall 8 news articles »
05/27/16 11:01 AMStock Rating Review for Aratana Therapeutics, Inc. (NASDAQ:PETX) - Wall Street Hints and News - Stock Rating Review for Aratana Therapeutics, Inc. (NASDAQ:PETX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.33 on shares of Aratana Therapeutics, Inc. (NASDAQ:PETX). Covering ...and more »
05/26/16 07:26 AMUpcoming Earnings Report: Aratana Therapeutics, Inc. (NASDAQ:PETX) - iStreetWire - Upcoming Earnings Report: Aratana Therapeutics, Inc. (NASDAQ:PETX)iStreetWireAratana Therapeutics, Inc. (PETX) retreated -1.1% to reach at the floor price of $6.31 as the company is set to share its next quarterly earnings on August 09, 2016. PETX stock trades between $6.23 and $6.53 before the earnings release. Let's take a ...Aratana Therapeutics Incorporated (NASDAQ:PETX) Shorted Shares Increased 0.16% After Market SellingWall Street Hints and Newsall 6 news articles »
05/24/16 02:29 PMETF’s with exposure to Aratana Therapeutics, Inc. : May 24, 2016 -
05/23/16 07:30 AMAratana Therapeutics to Participate at Two Upcoming Investor Conferences - [PR Newswire] - LEAWOOD, Kan., May 23, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical ...
05/21/16 12:25 PMLatest Aratana Therapeutics, Inc. (NASDAQ:PETX) Target Price Suggests Stock Is Worth $12.33/Share - Aratana Therapeutics, Inc. (PETX) up 1.31 per cent in the past week, is under coverage of 7 analysts who collectively recommend a buy rating on stock. 6 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 6 equity analysts ...
05/19/16 12:26 PMAratana Therapeutics Inc. (PETX) Jumps 7.6% on May 16 - Equities.com - Aratana Therapeutics Inc. (PETX) Jumps 7.6% on May 16Equities.comAratana Therapeutics Inc. (PETX) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 7.6% to $6.09, representing a gain of $0.43 per share. Some 480,092 shares traded hands on 2,871 trades, compared with an ...and more »
05/19/16 12:26 PMDog Drug Approval Drives Aratana Therapeutics Inc (PETX) Higher - Schaeffers Research (blog) - Schaeffers Research (blog)Dog Drug Approval Drives Aratana Therapeutics Inc (PETX) HigherSchaeffers Research (blog)Aratana Therapeutics Inc (NASDAQ:PETX) has jumped 5% at $6.35, after the veterinary drugmaker's appetite stimulant for dogs received Food and Drug Administration (FDA) approval. The move higher should come as a welcome development in the options ...Aratana Therapeutics Inc (PETX) Rises as FDA Approves Entyce for Dogs' InappetenceBidness ETCRevenue Update on Aratana Therapeutics Inc(NASDAQ:PETX)Trade CallsAratana Therapeutics (PETX) Announces FDA Approval of ENTYCE for Appetite Stimulation in DogsStreetInsider.comFranklin Independent -Kansas City Business Journal -NYSE Journal (press release)all 20 news articles »
05/18/16 01:08 PMPETX Has Its Day, AXIM On A High, CPRX Hands Out Pink Slips, CHRS Abuzz - Aratana Therapeutics Inc.'s (PETX) Entyce has been approved by the FDA's Center for Veterinary Medicine for appetite stimulation in dogs. The company intends to commercially launch the product in conjunction with the North American Veterinary Conference in ...
05/18/16 01:08 PMAratana Therapeutics (PETX) Announces FDA Approval of ENTYCE for Appetite Stimulation in Dogs - Claim your 2-week free trial to StreetInsider Premium here. Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals ...
05/18/16 01:08 PMDog Drug Approval Drives Aratana Therapeutics Inc (PETX) Higher - Aratana Therapeutics Inc (NASDAQ:PETX) has jumped 5% at $6.35, after the veterinary drugmaker's appetite stimulant for dogs received Food and Drug Administration (FDA) approval. The move higher should come as a welcome development in the options pits ...
05/18/16 01:08 PMAratana Therapeutics Inc (PETX) Rises as FDA Approves Entyce for Dogs’ Inappetence - Aratana Therapeutics Inc. (NASDAQ:PETX) stock shot up as high as 3.97% today, after the company announced that the Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) has approved Entyce, which is a treatment to stimulate dogs ...
05/17/16 05:31 PMU.S. FDA approves first appetite-stimulating drug for dogs - [Reuters] - The U.S. Food and Drug Administration approved the first drug to stimulate appetite in dogs, Aratana Therapeutics Inc, which developed the treatment, said on Tuesday. The drug, Entyce, is a flavored oral liquid that works by mimicking ghrelin, the hunger hormone, and will be launched by February 2017, the company said. Nearly 10 million dogs suffer from a lack of appetite, Chief Executive Steven Peter said in a statement.
05/17/16 04:46 PMAratana Therapeutics Granted FDA Approval of ENTYCE® (capromorelin oral solution) - [PR Newswire] - LEAWOOD, Kan., May 17, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in conjunction with the North American Veterinary Conference in February 2017. "Nearly 10 million dogs are diagnosed with inappetence each year and we believe Entyce will fulfill a significant unmet need to stimulate appetite in dogs," explains Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics.
05/17/16 02:42 PMAratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 01:23 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Hovering Around $6.09 - Investor Newswire - Aratana Therapeutics, Inc. (NASDAQ:PETX) Hovering Around $6.09Investor NewswireOn performing technical analysis of Aratana Therapeutics, Inc. (NASDAQ:PETX) stock, it is noted that the stock is $-0.09 points away -1.41% from its fifty-day MA of $6.22. It is $0.99 or +19.23% away $5.14, the 200-day MA (Moving Average) of stock ...and more »
05/14/16 06:43 AMConsensus Rating Review for Aratana Therapeutics, Inc. (NASDAQ:PETX) - Wall Street Hints and News - Consensus Rating Review for Aratana Therapeutics, Inc. (NASDAQ:PETX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.33 on shares of Aratana Therapeutics, Inc. (NASDAQ:PETX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/14/16 06:43 AMAratana Therapeutics Inc. (PETX) Drops 9.85% on May 12 - Equities.com - Aratana Therapeutics Inc. (PETX) Drops 9.85% on May 12Equities.comAratana Therapeutics Inc. (PETX) was one of the Russell 2000's biggest losers for Thursday May 12 as the stock slid 9.85% to $5.49, a loss of $-0.6 per share. Starting at an opening price of $6.12 a share, the stock traded between $5.47 and $6.18 over ...Aratana Therapeutics, Inc. (PETX) Latest Broker ViewsRisers & Fallersall 13 news articles »
05/13/16 12:04 PMARATANA THERAPEUTICS, INC. Financials -
05/12/16 07:11 AMCraig Hallum Comments on Aratana Therapeutics Inc's FY2016 Earnings (PETX) - Washington News Wire - Washington News WireCraig Hallum Comments on Aratana Therapeutics Inc's FY2016 Earnings (PETX)Washington News WireAratana Therapeutics logo Aratana Therapeutics Inc (NASDAQ:PETX) – Equities researchers at Craig Hallum reduced their FY2016 earnings per share estimates for shares of Aratana Therapeutics in a note issued to investors on Monday, Zacks Investment ...Aratana Therapeutics Inc. (PETX) Jumps 5.25% on May 10Equities.comStock Earnings Report: Aratana Therapeutics Inc (NASDAQ:PETX)News OracleAratana Therapeutics Incorporated (NASDAQ:PETX) Sellers Covered 10.12% of Their ShortsThe PostTheStreet.comall 7 news articles »
05/09/16 06:44 AMAnalyst's Overview of Two Stocks: Centene Corporation (NYSE:CNC) , Aratana Therapeutics, Inc. (NASDAQ:PETX) - Street Updates - Analyst's Overview of Two Stocks: Centene Corporation (NYSE:CNC) , Aratana Therapeutics, Inc. (NASDAQ:PETX)Street UpdatesCentene Corporation (NYSE:CNC) decreased -1.52% or -0.92 points. The company traded volume of 1.3 million shares less than average volume of 3.05 million shares. It has the market value of $7.27B and its EPS ratio for the past year is recorded at 2.88.5 Stocks Under Wall Street's Radar: Aratana Therapeutics, Inc. (NASDAQ:PETX), Exxon Mobil (NYSE:XOM), Mastech ...KC RegisterAratana Therapeutics Incorporated (NASDAQ:PETX) Shorted Shares Decreased By 10.12%The Postall 3 news articles »
05/06/16 12:31 PMEdited Transcript of PETX earnings conference call or presentation 6-May-16 12:30pm GMT -
05/06/16 07:45 AMARATANA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/06/16 06:54 AMAratana Therapeutics Inc. (PETX) Drops 5.03% on May 04 - Equities.com - Aratana Therapeutics Inc. (PETX) Drops 5.03% on May 04Equities.comAratana Therapeutics Inc. (PETX) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 5.03% to $5.67, a loss of $-0.3 per share. Starting at an opening price of $5.85 a share, the stock traded between $5.54 and $6.11 over ...and more »
05/05/16 05:38 PMAratana reports 1Q loss -
05/05/16 03:42 PMARATANA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
05/05/16 03:35 PM4:35 pm Aratana Therapeutics misses by $0.09, beats on revs -
05/05/16 03:05 PMAratana Therapeutics Reports First Quarter 2016 Financial Results - [PR Newswire] - LEAWOOD, Kan., May 5, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical ...
05/05/16 06:07 AMQ1 2016 Aratana Therapeutics Inc Earnings Release - After Market Close -
04/25/16 03:10 PMAratana Therapeutics to Discuss Global Strategic Collaboration with Elanco Animal Health - [PR Newswire] - LEAWOOD, Kan., April 25, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical ...
About Aratana Therapeutics

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both. The Company's target indications include pain and inflammation associated with osteoarthritis, inappetence, post-operative pain, lymphoma, osteosarcoma, atopic dermatitis, ocular herpes and feline immunodeficiency virus. The Company's most advanced products from a development and commercialization perspective, AT-004 and AT-005, are monoclonal antibodies (MAbs) for treating lymphoma in dogs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PETX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.86
  • 50 Day Moving Average: $6.42
  • 200 Day Moving Average: $5.18
  • P/E Ratio: N/A
  • P/E Growth: -0.38
  • Market Cap: $217.38M
  • Current Quarter EPS Consensus Estimate: $-1.08 EPS
Additional Links:
Aratana Therapeutics (NASDAQ:PETX) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha